Loss of heterozygosity of 3p markers in neuroblastoma tumours implicate a tumour-suppressor locus distal to the FHIT gene
- PMID: 9667647
- PMCID: PMC2150348
- DOI: 10.1038/bjc.1998.297
Loss of heterozygosity of 3p markers in neuroblastoma tumours implicate a tumour-suppressor locus distal to the FHIT gene
Abstract
Neuroblastoma is a heterogeneous childhood tumour of the sympathetic nervous system, in which deletions of chromosomal region 1p and amplification of the MYCN oncogene correlate with aggressive tumour behaviour. However, the majority of neuroblastoma tumours show neither of these aberrations, indicating that other chromosomal regions may be involved in tumorigenesis. Here, we report findings of loss of heterozygosity (LOH) on chromosome 3. In our neuroblastoma material, nine of 59 (15.3%) tested tumours showed allelic loss of chromosome 3p markers. We found significant clinical and biological differences between tumours with the loss of one entire chromosome 3 vs tumours with partial loss in chromosome region 3p. All children with tumours with whole chromosome 3 loss are long-term survivors, whereas all children with tumours showing partial 3p LOH have died from tumour progression. A consensus region found to be deleted in all the tumours with 3p deletions was defined by markers D3S1286 and D3S1295, i.e. 3p25.3-p14.3, distal to the FHIT gene.
Similar articles
-
Delimitation of a critical tumour suppressor region at distal 1p in neuroblastoma tumours.Eur J Cancer. 1997 Oct;33(12):1997-2001. doi: 10.1016/s0959-8049(97)00278-5. Eur J Cancer. 1997. PMID: 9516841
-
Representational difference analysis and loss of heterozygosity studies detect 3p deletions in neuroblastoma.Eur J Cancer. 1997 Oct;33(12):1966-70. doi: 10.1016/s0959-8049(97)00228-1. Eur J Cancer. 1997. PMID: 9516834
-
Investigation of tumor suppressor genes apart from VHL on 3p by deletion mapping in sporadic clear cell renal cell carcinoma (cRCC).Urol Oncol. 2013 Oct;31(7):1333-42. doi: 10.1016/j.urolonc.2011.08.012. Epub 2011 Oct 1. Urol Oncol. 2013. PMID: 21962529
-
Amplification of the MYCN oncogene and deletion of putative tumour suppressor gene in human neuroblastomas.Brain Pathol. 1990 Sep;1(1):41-6. doi: 10.1111/j.1750-3639.1990.tb00637.x. Brain Pathol. 1990. PMID: 1669692 Review.
-
Analysis of genomic imprinting at 1p35-36 in neuroblastoma.Med Pediatr Oncol. 2001 Jan;36(1):52-5. doi: 10.1002/1096-911X(20010101)36:1<52::AID-MPO1014>3.0.CO;2-8. Med Pediatr Oncol. 2001. PMID: 11464906 Review.
Cited by
-
cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma.BMC Genomics. 2004 Sep 20;5:70. doi: 10.1186/1471-2164-5-70. BMC Genomics. 2004. PMID: 15380028 Free PMC article.
-
SLIT2 promoter methylation analysis in neuroblastoma, Wilms' tumour and renal cell carcinoma.Br J Cancer. 2004 Jan 26;90(2):515-21. doi: 10.1038/sj.bjc.6601447. Br J Cancer. 2004. PMID: 14735202 Free PMC article.
-
Multiple mechanisms disrupt the let-7 microRNA family in neuroblastoma.Nature. 2016 Jul 14;535(7611):246-51. doi: 10.1038/nature18632. Epub 2016 Jul 6. Nature. 2016. PMID: 27383785 Free PMC article.
-
Gene Expression Signature of Acquired Chemoresistance in Neuroblastoma Cells.Int J Mol Sci. 2020 Sep 16;21(18):6811. doi: 10.3390/ijms21186811. Int J Mol Sci. 2020. PMID: 32948088 Free PMC article.
-
CHL1 gene acts as a tumor suppressor in human neuroblastoma.Oncotarget. 2018 May 25;9(40):25903-25921. doi: 10.18632/oncotarget.25403. eCollection 2018 May 25. Oncotarget. 2018. PMID: 29899830 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials